“Hopefully, this statement will enable health-care providers to offer those women in midlife, who may benefit from MHT, the opportunity to make an informed decision”.1
Umbrella
What may the Hormone Therapy 2016 Revised Global Consensus Statement Umbrella include?
Depending on the Source (DotS) this Umbrella may include:
- Hormone Replacement Therapy (HRT)
- Hormone Therapy (HT)
- Menopausal Hormone Therapy (MHT)
- Revised Global Consensus Statement on Menopausal Hormone Therapy
Revised Global Consensus Statement
What is the Revised Global Consensus Statement on Menopausal Hormone Therapy?
In the Revised Global Consensus Statement on Menopausal Hormone Therapy (Revised Global Consensus Statement) – endorsed by seven menopause-related organizations – published online 20 June 2016, the authors explain:
Organizations
Which organizations endorse the Revised Global Consensus Statement?
Organizations which endorse the Revised Global Consensus Statement (in alphabetical order) are the:
- Asia Pacific Menopause Federation
- Endocrine Society
- European Menopause and Andropause Society
- Federation of Latin American Menopause Societies
- International Menopause Society
- International Osteoporosis Foundation
- North American Menopause Society
Hopeful
What are the Revised Global Consensus Statement authors hopeful of?
The Revised Global Consensus Statement authors note:
“Hopefully, this statement will enable health-care providers to offer those women in midlife, who may benefit from MHT, the opportunity to make an informed decision”.3
Acknowledgement
What do the Revised Global Consensus Statement authors acknowledge?
The Revised Global Consensus Statement authors acknowledge:
Consensus
What are some points of consensus in the Revised Global Consensus Statement?
Some points of consensus are:
- “MHT, including tibolone and the combination of conjugated equine estrogens and bazedoxifene (CE/BZA), is the most effective treatment for vasomotor symptoms (VMS) associated with menopause at any age, but benefits are more likely to outweigh risks if initiated for symptomatic women before the age of 60 years or within 10 years after menopause
- If MHT is contraindicated or not desired for treatment of VMS, selective serotonin reuptake inhibitors and serotoninnorepinephrine reuptake inhibitors such as paroxetine, escitalopram, venlafaxine and desvenlafaxine, which have been shown to be effective in randomized controlled trials (RCTs), may be considered. Gabapentin may also be considered
- Local low-dose estrogen therapy is preferred for women whose symptoms are limited to vaginal dryness or associated discomfort with intercourse or for the prevention of recurrent urinary tract infections”.5
Vasomotor Symptoms
What are vasomotor symptoms?
DotS the definition of vasomotor symptoms may vary. The North American Menopause Society’s definition is:
Health Care Provider
What if I choose to use MHT?
If you choose to use MHT, it may be in your best interest to also choose to talk to your health care provider about this.
One of the points of consensus in the Revised Global Consensus Statement is:
- “The option of MHT is an individual decision in terms of quality of life and health priorities as well as personal risk factors such as age, time since menopause and the risk of VTE, stroke, ischemic heart disease and breast cancer. MHT should not be recommended without a clear indication for its use”.7
What is VTE?
MHT can be an abbreviation for Venous Thromboembolism.
Health Topics A-Z
Where may I find Health Topics related to Hormone Therapy 2016 Global Consensus Statement?
In Health Topics A-Z you may find:
Links
Where may I find Links related to Hormone Therapy 2016 Global Consensus Statement?
Your Country may have Links similar to:
Links
This Links List to third party websites is neither comprehensive nor exhaustive. Inclusion on this Links List does not imply endorsement or recommendation. Non-inclusion on this Links List does not imply non-endorsement or non-recommendation. Third party websites are not under the control of Meno Martha International Menopause Directory. Third party websites may contain explicit medical images and/or sexual references. Please read Meno Martha International Menopause Directory’s Links Policy before proceeding to a Link. Please contact Webmaster if you experience a problem with a Link.- 2016 IMS Recommendations on Women’s Midlife Health and Menopause Hormone Therapy
- 9 Myths and Misunderstandings About Menopausal Hormone Therapy (MHT): 6. Myth – Complementary Medicines and Therapies Are As Effective As MHT and Safer
- 9 Myths and Misunderstandings About Menopausal Hormone Therapy (MHT): 7. Myth – Compounded Bioidentical Hormone Therapy Is Safer Than Conventional MHT
- Bioidentical Custom Compounded Hormone Therapy
- Bioidentical Hormone Therapy
- Bioidentical Hormones Explained – A British Menopause Society Video
- Bioidentical Hormones: Are They Safer?
- Combined Menopausal Hormone Therapy (MHT)
- Complementary Medicine Options for Menopausal Symptoms
- Complementary and Alternative Therapies Explained – A British Menopause Society Video
- Compounded Bioidentical Hormone Therapy [Video]
- Compounded Bioidentical Hormones In Endocrinology Practice: An Endocrine Society Scientific Statement
- Deciding About Hormone Therapy
- Deciding About Hormone Therapy Use
- Decidir Sobre La Hormonoterapia
- Early Menopause: Experiences and Perspectives of Women and Health Practitioners – Women’s Profiles
- Estrogen & Hormones: Estrogen & Heart Disease
- Global Consensus Statement on Menopausal Hormone Therapy [2013]
- HRT and Bleeding Explained – A British Menopause Society Video
- HRT and Breast Cancer: Overall Risks and Benefits Explained – A British Menopause Society Video
- HRT and the Risk of Breast Cancer Explained – A British Menopause Society Video
- HRT: The History
- Hormone Help Desk: ET, EPT, and More
- Hormone Replacement Therapy
- Hormone Replacement Therapy (HRT)
- Hormone Replacement Therapy (HRT) Explained – A British Menopause Society Video
- Hormone Replacement Therapy (HRT): Risks of HRT
- Hormone Replacement Therapy (HRT): Types
- Hormone Therapy: Is It Right for You?
- Hormones After Age 65 Are OK for Some Women
- Hot Flash Relief Without Hormones
- Hot Flashes: Manage Without Medication?
- Hot Flashes: What Can I Do?
- Hot Stuff: What’s New About Hot Flashes?
- Index To Drug-Specific Information [United States]
- Information About Menopause [Multiply Languages] [Videos]
- Jean Hailes MHT Position Statement
- La Menopausia Y Las Hormonas: Preguntas Para Su Médico
- Lifestyle and Behaviour Changes for Menopausal Symptoms
- Lifestyle and Behavioural Modifications for Menopausal Symptoms
- MHT and Breast Cancer Risk
- Making Choices At Menopause
- Making Sense of Menopausal Hormone Therapy Means Understanding the Benefits As Well As the Risks
- Managing Menopausal Symptoms After Breast Cancer – A Guide for Women [Booklet]
- Mayo Clinic Q and A: Estrogen Replacement Therapy After Ovary Removal
- Menopause
- Menopause
- Menopause
- Menopause
- Menopause & Hormones: Questions To Ask Your Doctor
- Menopause FAQs: Hormone Therapy for Menopause Symptoms
- Menopause Hormone Therapy and Your Heart
- Menopause Hormone Therapy: Follow-Up Appointments
- Menopause Hormone Therapy: Who Shouldn’t Take It?
- Menopause Matters
- Menopause Symptoms and Relief
- Menopause Treatment
- Menopause What Are the Symptoms?
- Menopause – Is Menopausal Hormone Therapy (HRT) Safe? [Multiply Languages] [Video]
- Menopause – What Is Menopausal Hormone Therapy (HRT)? [Multiply Languages] [Video]
- Menopause: Diagnosis and Management – Information for the Public: Questions To Ask About Menopause [NICE Guideline]
- Menopause: Hormone Replacement Therapy (HRT) [Video Interview Stories]
- Menopause: Medicines To Help You
- Menopause: Menopause – Hormone Treatments
- Menopause: Non-HRT and Lifestyle Options [Video Interview Stories]
- Menopause: Non-Hormonal Treatment & Relief for Hot Flashes
- Misperceptions From WHI Prevent Women from Benefitting from Hormone Therapy
- NAMS 2017 Position Statement Updates Guidelines for Hormone Therapy Use
- NAMS Supports Judicious Use of Systemic Hormone Therapy for Women Aged 65 Years and Older
- National Center for Complementary and Integrative Health: 4 Things To Know About Menopausal Symptoms and Complementary Health Practices
- National Center for Complementary and Integrative Health: Herbs At A Glance
- National Center for Complementary and Integrative Health: How Safe Is This Product or Practice?
- National Center for Complementary and Integrative Health: Know the Science: How Medications and Supplements Can Interact
- National Center for Complementary and Integrative Health: Menopausal Symptoms In Depth
- Non-Hormonal Treatment Options for Menopausal Symptoms
- NonHormonal Treatments for Menopausal Symptoms
- Oestrogen Only Menopausal Hormone Therapy
- Office of Dietary Supplements: Black Cohosh
- Office of Dietary Supplements: Dietary Supplement Fact Sheets
- Practical Prescribing Explained – A British Menopause Society Video
- Revised Global Consensus Statement on Menopausal Hormone Therapy
- Risks and Benefits of MHT/HRT
- Testosterone Explained – A British Menopause Society Video
- The North American Menopause Society Statement on Continuing Use of Systemic Hormone Therapy After Age 65
- Tipos de Hormonoterapia
- Types of Hormone Therapy
- Understanding Menopause – Booklet
- Understanding Premature & Early Menopause – Booklet
- Urogenital Atrophy Explained – A British Menopause Society Video
- Urogenital Problems
- Using HRT (Hormone Replacement Therapy)
- Vaginal Dryness
- Vaginal Dryness
- Video Gallery [Menopause, The Journal of the North American Menopause Society]
- Video Series-2020 – TSECs—A New Treatment for Hot Flashes and Night Sweats
- Video Series-2020 – What You Need To Know About Bioidentical Hormone Therapy
What Is Menopausal Hormone Therapy (MHT) and Is It Safe?
- Women Can Breathe Sigh of Relief When Using Vaginal Estrogen To Treat Menopause Symptoms
- Women’s Wellness: Treating Hot Flashes Without Hormones
Sources
Where may I find the Sources quoted?
You may find the Sources quoted at:
Sources
- De Villiers, T. J., Hall, J. E., Pinkerton, J. V., Pérez, S. C., Rees, M., Yang, C. and Pierroz, D. D. Revised Global Consensus Statement on Menopausal Hormone Therapy: Introduction. Climacteric, 2016;19:4:313 https://www.imsociety.org/manage/images/pdf/ba6379e868044bec13015ac2b84f2753.pdf Accessed: 16 October 2020
- De Villiers, T. J., Hall, J. E., Pinkerton, J. V., Pérez, S. C., Rees, M., Yang, C. and Pierroz, D. D. Revised Global Consensus Statement on Menopausal Hormone Therapy: Introduction. Climacteric, 2016;19:4:313 https://www.imsociety.org/manage/images/pdf/ba6379e868044bec13015ac2b84f2753.pdf Accessed: 16 October 2020
- De Villiers, T. J., Hall, J. E., Pinkerton, J. V., Pérez, S. C., Rees, M., Yang, C. and Pierroz, D. D. Revised Global Consensus Statement on Menopausal Hormone Therapy: Introduction. Climacteric, 2016;19:4:313 https://www.imsociety.org/manage/images/pdf/ba6379e868044bec13015ac2b84f2753.pdf Accessed: 16 October 2020
- De Villiers, T. J., Hall, J. E., Pinkerton, J. V., Pérez, S. C., Rees, M., Yang, C. and Pierroz, D. D. Revised Global Consensus Statement on Menopausal Hormone Therapy: Introduction. Climacteric, 2016;19:4:313 https://www.imsociety.org/manage/images/pdf/ba6379e868044bec13015ac2b84f2753.pdf Accessed: 16 October 2020
- De Villiers, T. J., Hall, J. E., Pinkerton, J. V., Pérez, S. C., Rees, M., Yang, C. and Pierroz, D. D. Revised Global Consensus Statement on Menopausal Hormone Therapy: Section A: Benefit/Risk Profile of MHT. Climacteric, 2016;19:4:313 https://www.imsociety.org/manage/images/pdf/ba6379e868044bec13015ac2b84f2753.pdf Accessed: 16 October 2020
- Menopause Glossary: V – Vasomotor Symptoms. North American Menopause Society http://www.menopause.org/for-women/menopause-glossary#V Accessed: 16 October 2020
- De Villiers, T. J., Hall, J. E., Pinkerton, J. V., Pérez, S. C., Rees, M., Yang, C. and Pierroz, D. D. Revised Global Consensus Statement on Menopausal Hormone Therapy: Section B: General Principles Governing the Use of MHT. Climacteric, 2016;19:4:314 https://www.imsociety.org/manage/images/pdf/ba6379e868044bec13015ac2b84f2753.pdf Accessed: 16 October 2020